Viking Therapeutics (VKTX) Stock Price, News & Analysis

Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $24.96 to $26.65
• 50-Day Range: $24.36 to $42.09
• 52-Week Range: $18.92 to $81.73
• Volume: 10.55 million shs
• Average Volume: 8.76 million shs
• Market Capitalization: $2.92 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $86.92
• Consensus Rating: Buy

Viking Therapeutics Stock Analysis - MarketRank™

Viking Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 215th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Viking Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Viking Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Viking Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Viking Therapeutics is -16.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Viking Therapeutics is -16.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Viking Therapeutics has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.61% of the float of Viking Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viking Therapeutics has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Viking Therapeutics has recently increased by 0.35%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Viking Therapeutics does not currently pay a dividend.

Dividend Growth

Viking Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.88

Percentage of Shares Shorted

26.61% of the float of Viking Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Viking Therapeutics has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Viking Therapeutics has recently increased by 0.35%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.06

News Sentiment

Viking Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 43 news articles for Viking Therapeutics this week, compared to 15 articles on an average week.

Search Interest

86 people have searched for VKTX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.

MarketBeat Follows

38 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 46% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Viking Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $984,405.00 in company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Viking Therapeutics is held by insiders.

Percentage Held by Institutions

76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VKTX Stock Analysis - Frequently Asked Questions

How have VKTX shares performed this year?

Viking Therapeutics' stock was trading at $40.24 at the start of the year. Since then, VKTX stock has decreased by 35.4% and is now trading at $26.00.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) released its earnings results on Wednesday, July, 23rd. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.14. Viking Therapeutics's quarterly revenue was up NaN% on a year-over-year basis.
Read the conference call transcript.

When did Viking Therapeutics IPO?

Viking Therapeutics (VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO and Feltl and Company was co-manager.

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' top institutional investors include State Street Corp (3.36%), Geode Capital Management LLC (1.71%), Norges Bank (1.57%) and Ameriprise Financial Inc. (1.31%). Insiders that own company stock include Brian Lian, Marianna Mancini, Greg Zante, Lawson Macartney, Charles A Rowland Jr, J Matthew Singleton and Sarah Kathryn Rouan.
View institutional ownership trends.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Invesco QQQ (QQQ), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 7/23/2025
• Today: 8/24/2025
• Next Earnings (Estimated): 10/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VKTX
• CIK: 1607678
• Web: www.vikingtherapeutics.com
• Phone: (858) 704-4660
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Viking Therapeutics: $86.92
• High Price Target: $138.00
• Low Price Target: $30.00
• Potential Upside/Downside: +234.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$109.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.98%
• Return on Assets: -19.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.86
• Quick Ratio: 25.86

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.07 per share
• Price / Book: 3.68

Miscellaneous

• Outstanding Shares: 112,440,000
• Free Float: 107,835,000
• Market Cap: $2.92 billion
• Optionable: Optionable
• Beta: 0.67